582 related articles for article (PubMed ID: 29098609)
1. Methods of Detection of Measurable Residual Disease in AML.
Zhou Y; Wood BL
Curr Hematol Malig Rep; 2017 Dec; 12(6):557-567. PubMed ID: 29098609
[TBL] [Abstract][Full Text] [Related]
2. Optimal Measurable Residual Disease Testing for Acute Myeloid Leukemia.
Xiao W; Petrova-Drus K; Roshal M
Surg Pathol Clin; 2019 Sep; 12(3):671-686. PubMed ID: 31352980
[TBL] [Abstract][Full Text] [Related]
3. High prognostic impact of flow cytometric minimal residual disease detection in acute myeloid leukemia: data from the HOVON/SAKK AML 42A study.
Terwijn M; van Putten WL; Kelder A; van der Velden VH; Brooimans RA; Pabst T; Maertens J; Boeckx N; de Greef GE; Valk PJ; Preijers FW; Huijgens PC; Dräger AM; Schanz U; Jongen-Lavrecic M; Biemond BJ; Passweg JR; van Gelder M; Wijermans P; Graux C; Bargetzi M; Legdeur MC; Kuball J; de Weerdt O; Chalandon Y; Hess U; Verdonck LF; Gratama JW; Oussoren YJ; Scholten WJ; Slomp J; Snel AN; Vekemans MC; Löwenberg B; Ossenkoppele GJ; Schuurhuis GJ
J Clin Oncol; 2013 Nov; 31(31):3889-97. PubMed ID: 24062400
[TBL] [Abstract][Full Text] [Related]
4. Test Then Erase? Current Status and Future Opportunities for Measurable Residual Disease Testing in Acute Myeloid Leukemia.
Blackmon AL; Hourigan CS
Acta Haematol; 2024; 147(2):133-146. PubMed ID: 38035547
[TBL] [Abstract][Full Text] [Related]
5. The emerging role of measurable residual disease detection in AML in morphologic remission.
Buccisano F; Maurillo L; Schuurhuis GJ; Del Principe MI; Di Veroli A; Gurnari C; Venditti A
Semin Hematol; 2019 Apr; 56(2):125-130. PubMed ID: 30926088
[TBL] [Abstract][Full Text] [Related]
6. Role of minimal residual disease in the management of acute myeloid leukemia-a case-based discussion.
Coltoff A; Houldsworth J; Keyzner A; Renteria AS; Mascarenhas J
Ann Hematol; 2018 Jul; 97(7):1155-1167. PubMed ID: 29704019
[TBL] [Abstract][Full Text] [Related]
7. Minimal/Measurable Residual Disease Monitoring in
Forghieri F; Comoli P; Marasca R; Potenza L; Luppi M
Int J Mol Sci; 2018 Nov; 19(11):. PubMed ID: 30404199
[TBL] [Abstract][Full Text] [Related]
8. [Prognosticating relapse risk based on multiparameter flow cytometric assessment of minimal residual disease in patients with acute myeloid leukemia].
Wan SG; Zhao H; Sun XJ; He JJ; Su L; Xu J
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Jun; 17(3):557-62. PubMed ID: 19549363
[TBL] [Abstract][Full Text] [Related]
9. Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia.
Cloos J; Harris JR; Janssen JJWM; Kelder A; Huang F; Sijm G; Vonk M; Snel AN; Scheick JR; Scholten WJ; Carbaat-Ham J; Veldhuizen D; Hanekamp D; Oussoren-Brockhoff YJM; Kaspers GJL; Schuurhuis GJ; Sasser AK; Ossenkoppele G
J Vis Exp; 2018 Mar; (133):. PubMed ID: 29553571
[TBL] [Abstract][Full Text] [Related]
10. Measurement of Residual Disease in Acute Myeloid Leukemia.
Vedula RS; Lindsley RC
Curr Hematol Malig Rep; 2017 Dec; 12(6):574-581. PubMed ID: 29064024
[TBL] [Abstract][Full Text] [Related]
11. Minimal Residual Disease in Acute Myeloid Leukemia.
Gomez-Arteaga A; Guzman ML
Adv Exp Med Biol; 2018; 1100():111-125. PubMed ID: 30411263
[TBL] [Abstract][Full Text] [Related]
12. Measurable residual disease assessment by qPCR in peripheral blood is an informative tool for disease surveillance in childhood acute myeloid leukaemia.
Juul-Dam KL; Ommen HB; Nyvold CG; Walter C; Vålerhaugen H; Kairisto V; Abrahamsson J; Alm SJ; Jahnukainen K; Lausen B; Reinhardt D; Zeller B; von Neuhoff N; Fogelstrand L; Hasle H
Br J Haematol; 2020 Jul; 190(2):198-208. PubMed ID: 32175599
[TBL] [Abstract][Full Text] [Related]
13. Minimal/Measurable Residual Disease Detection in Acute Leukemias by Multiparameter Flow Cytometry.
Fuda F; Chen W
Curr Hematol Malig Rep; 2018 Dec; 13(6):455-466. PubMed ID: 30446941
[TBL] [Abstract][Full Text] [Related]
14. Clinical Use of Measurable Residual Disease in Acute Myeloid Leukemia.
Roug AS; Ommen HB
Curr Treat Options Oncol; 2019 Mar; 20(4):28. PubMed ID: 30874904
[TBL] [Abstract][Full Text] [Related]
15. The Prognostic Significance of Measurable ("Minimal") Residual Disease in Acute Myeloid Leukemia.
Buccisano F; Hourigan CS; Walter RB
Curr Hematol Malig Rep; 2017 Dec; 12(6):547-556. PubMed ID: 29027628
[TBL] [Abstract][Full Text] [Related]
16. 2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party.
Heuser M; Freeman SD; Ossenkoppele GJ; Buccisano F; Hourigan CS; Ngai LL; Tettero JM; Bachas C; Baer C; Béné MC; Bücklein V; Czyz A; Denys B; Dillon R; Feuring-Buske M; Guzman ML; Haferlach T; Han L; Herzig JK; Jorgensen JL; Kern W; Konopleva MY; Lacombe F; Libura M; Majchrzak A; Maurillo L; Ofran Y; Philippe J; Plesa A; Preudhomme C; Ravandi F; Roumier C; Subklewe M; Thol F; van de Loosdrecht AA; van der Reijden BA; Venditti A; Wierzbowska A; Valk PJM; Wood BL; Walter RB; Thiede C; Döhner K; Roboz GJ; Cloos J
Blood; 2021 Dec; 138(26):2753-2767. PubMed ID: 34724563
[TBL] [Abstract][Full Text] [Related]
17. Minimal residual disease monitoring in acute myeloid leukemia: Focus on MFC-MRD and treatment guidance for elderly patients.
Sun Y; Zhu G; Zhong H
Eur J Haematol; 2024 Jun; 112(6):870-878. PubMed ID: 38342613
[TBL] [Abstract][Full Text] [Related]
18. Measurable residual disease conversion rate with consolidation chemotherapy in acute myeloid leukemia.
Gaut D; Oliai C; Boiarsky J; Zhang S; Salhotra A; Azenkot T; Kennedy VE; Khanna V; Olmedo Gutierrez K; Shukla N; Moskoff B; Park G; Afkhami M; Patel A; Jeyakumar D; Mannis G; Logan AC; Jonas BA; Schiller G
Leuk Lymphoma; 2024 Jan; 65(1):69-77. PubMed ID: 37801340
[TBL] [Abstract][Full Text] [Related]
19. Predictive factors of relapse and survival in childhood acute myeloid leukemia: role of minimal residual disease.
Rizzari C; Cazzaniga G; Coliva T; De Angelis C; Conter V
Expert Rev Anticancer Ther; 2011 Sep; 11(9):1391-401. PubMed ID: 21929313
[TBL] [Abstract][Full Text] [Related]
20. Measurable residual disease testing in acute myeloid leukaemia.
Hourigan CS; Gale RP; Gormley NJ; Ossenkoppele GJ; Walter RB
Leukemia; 2017 Jul; 31(7):1482-1490. PubMed ID: 28386105
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]